Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Receivables (2018 - 2025)

Historic Receivables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $11.1 million.

  • Exagen's Receivables rose 1824.86% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 1824.86%. This contributed to the annual value of $7.8 million for FY2024, which is 1871.21% up from last year.
  • Latest data reveals that Exagen reported Receivables of $11.1 million as of Q3 2025, which was up 1824.86% from $14.3 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Receivables registered a high of $17.0 million during Q3 2023, and its lowest value of $6.1 million during Q4 2022.
  • For the 5-year period, Exagen's Receivables averaged around $10.6 million, with its median value being $9.7 million (2021).
  • In the last 5 years, Exagen's Receivables surged by 8628.8% in 2023 and then tumbled by 4492.49% in 2024.
  • Over the past 5 years, Exagen's Receivables (Quarter) stood at $9.7 million in 2021, then crashed by 37.11% to $6.1 million in 2022, then increased by 8.2% to $6.6 million in 2023, then rose by 18.71% to $7.8 million in 2024, then soared by 41.67% to $11.1 million in 2025.
  • Its Receivables was $11.1 million in Q3 2025, compared to $14.3 million in Q2 2025 and $14.7 million in Q1 2025.